Special Issue

Antiviral Immunity and Vaccine Development

Message from the Guest Editors

This Special Issue of Vaccines aims to bring together cutting-edge research on host immune responses to viral pathogens, thus providing insights into developing innovative antiviral vaccine technologies. This Special Issue will focus on a broad spectrum of topics, including the mechanisms of immune responses to viral infections, innovative adjuvants based on the modulation of immune signalling pathways, novel vaccine platforms (such as mRNA, vector-based, and protein subunit vaccines), and recent breakthroughs in vaccine design (such as reverse vaccinology, structurebased vaccine design, mucosal vaccines, etc.). We are particularly interested in highlighting research that expands the boundaries of current knowledge in vaccine development and contributes to our understanding of immunity against both emerging and established viral threats. This Special Issue welcomes submissions that provide important insights and novel conceptions of antiviral immune responses and vaccine development. Additionally, studies focusing on viral immune evasion mechanisms and innovative vaccine therapeutics are also highly encouraged.

Guest Editors

Prof. Dr. Caijun Sun

School of Public Health (Shenzhen), Sun Yat-Sen University, Shenzhen 518107, China

Dr. Tao Yu

Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

Deadline for manuscript submissions

30 April 2026



an Open Access Journal by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/225147

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

mdpi.com/journal/vaccines





an Open Access Journal by MDPI

Impact Factor 3.4 CiteScore 9.9 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).

